AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

计划入组 31 人 · 首次发布于 2017 年 8 月 18 日

(VELA) Study of BLU-222 in Advanced Solid Tumors

计划入组 50 人 · 首次发布于 2022 年 2 月 23 日

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

首次发布于 2016 年 1 月 15 日

CCNE1 (Fog Pharma)

CCNE1(Monte Rosa)

CCNE1 degrader (Fog pharma)

ON Semiconductor

FDA Grants Fast Track Designation to Incyclix Bio's INX-315 for CCNE1-Amplified Platinum-Resistant Ovarian Cancer

Repare Therapeutics to Present Phase 1 MYTHIC Trial Data of Lunresertib and Camonsertib Combination in Advanced Cancers

Repare Therapeutics Advances Oncology Pipeline with Promising Clinical Data